Experimental cancer drug trial halted early

NCT ID NCT05233436

First seen Feb 21, 2026 · Last updated Apr 30, 2026 · Updated 11 times

Summary

This early-stage study tested a new drug, PF-07265028, alone or with another drug (sasanlimab) in people with advanced solid tumors that had spread. The goal was to find a safe dose and see if the drug shrank tumors. The study was stopped early, and 21 people took part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • HonorHealth Research Institute

    Scottsdale, Arizona, 85258, United States

  • HonorHealth Scottsdale Shea Medical Center

    Scottsdale, Arizona, 85260, United States

  • Mary Crowley Cancer Research

    Dallas, Texas, 75230, United States

  • National Cancer Center Hospital East

    Kashiwa, Chiba, 277-8577, Japan

  • START Midwest

    Grand Rapids, Michigan, 49546, United States

  • South Texas Accelerated Research Therapeutics, LLC

    San Antonio, Texas, 78229, United States

  • The Cancer Institute Hospital of JFCR

    Koto, Tokyo, 135-8550, Japan

  • University of Iowa

    Iowa City, Iowa, 52242, United States

Conditions

Explore the condition pages connected to this study.